Participation in other studies involving investigational drug(s) within days prior to study entry. Participation in any other clinical trial involving another investigational agent within weeks prior to Day of the study. Participation in other studies involving investigational drug(s) within weeks prior to study entry Are currently enrolled in, or have discontinued within days of screening, from a clinical trial involving an investigational product or non-approved use of a drug or device. Participation in any study involving administration of an investigational agent within days of randomization into this study Have participated, within the last days in a clinical trial involving an investigational product or are currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study. Current enrollment in another clinical study involving treatment and/or is receiving an investigational agent for any reason, or use of any investigational agents within days of initiating study treatment. Participation in any other clinical trial involving another investigational agent within weeks prior to first dose of study agent Participation in any other clinical trial involving another investigational agent within weeks prior to first dosing of study drug Participation in any other research protocol involving administration of an investigational agent within month prior to study entry Participation in any other clinical trial involving another investigational agent within weeks prior to first immunization Participation in another clinical study involving an investigational product within month before study entry; Subjects may not be receiving any other investigational agents or have participated in any other clinical trial involving another investigational agent for treatment of advanced solid tumors or lymphoma within weeks prior to cycle , day of the study. Are currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study. Participation in any other clinical trial involving another investigational agent for the treatment of AML within weeks prior to day of the study or at least half-lives of the investigational agent, whichever is shorter Participation in other studies involving investigational drug(s) (phases -) within weeks before randomization in the current study Participation to a study involving a medical or therapeutic intervention in the last days Participation in a clinical study involving receipt of an investigational drug during the last days. Use of GSK (CPHPC), or participation in a separate clinical trial involving CPHPC within months of screening Previous treatment with crenolanib or prior participation in clinical trial involving crenolanib. Participation in any previous study involving sipuleucel-T Current participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this study Current participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this study Current participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this study Prior treatment in any other clinical trial involving another investigational agent within weeks prior to Day - of the study; resolution of respective adverse event to Grade or lower should have occurred Are currently receiving treatment in a clinical trial involving an investigational product or non-approved use of a drug or device. Participation in a clinical trial involving an investigational drug within days of study start The participant is currently enrolled in a clinical trial involving an investigational product or non-approved use of a drug or device. Participation in any other research protocol involving administration of an investigational agent within weeks prior to study entry Concurrent investigational therapy given to treat cancer or concurrent participation in another clinical trial involving anti-cancer investigational drug. Current enrollment in another clinical trial involving treatment and/or is receiving an investigational agent for any reason Current enrollment in another clinical trial involving treatment and/or is receiving an investigational agent for any reason Participant has participated in another clinical study involving an investigational product (IP) or investigational device within days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study Participation in any other clinical trial involving another investigational agent within weeks prior to day of the study. Is concurrently enrolled in another therapeutic clinical trial involving ongoing therapy with any investigational or marketed product or placebo. Participation in any other clinical trial involving another investigational agent within weeks prior to first dosing of study drug Enrolled in a clinical trial involving an investigational product or nonapproved use of a drug or in medical research judged not to be scientifically or medically compatible with this study. Concurrent participation in another study involving investigational drugs or investigational medical devices Participation in another clinical trial involving an investigational product within days prior to screening; or Previous participation in any clinical trial involving rolapitant Participation in another clinical trial involving an investigational agent within weeks of enrollment Participant in a clinical trial involving an investigational drug within the past days Patient has completed participation in another clinical study involving administration of an investigational agent in the preceding weeks. However, participation in clinical studies involving other investigational PET or SPECT tracers will not be excluded if in the opinion of the Investigator: Patient included in another clinical trial involving an IMP within days before the first investigational contrast agent injection.